From China-Originated Biotech Assets to U.S. Partnerships
From China-Originated Biotech Assets to U.S. Partnerships
A Private Venture Signal Breakfast Conversation
Wednesday, September 30, 2026 | 8:00–10:00 AM
Boston, Massachusetts
The exact address will be provided to approved participants.
This private working breakfast is designed for biotech companies that own or control promising preclinical or clinical assets and are actively exploring U.S. investment, licensing, pharmaceutical partnerships, or cross-border development.
This is not a general educational seminar. Priority will be given to founders, executives, scientific leaders, and business-development professionals who can discuss a specific asset, its current stage, and a defined partnering or readiness need.
Virtual participation: A limited number of approved virtual places are available for asset owners and company representatives outside the Boston area, including participants joining from China. The virtual portion will begin at 8:30 AM ET / 8:30 PM China Standard Time. This is an interactive working conversation rather than a public webinar; virtual participants should be prepared to introduce themselves and, if selected, briefly describe their asset and current partnering need.
What We Will Examine
The conversation will help participating companies consider four connected questions:
Investment readiness: Is the asset presented as a focused, differentiated, and investable opportunity?
Evidence readiness: Are the scientific, preclinical, clinical, regulatory, and commercial materials coherent, traceable, and easy to evaluate?
Legal readiness: Are IP ownership, confidentiality, corporate, contractual, and cross-border matters ready for diligence?
Pharma engagement: Is the company approaching appropriate contacts with a clear clinical and competitive proposition and materials that can circulate internally?
The final segment will invite selected participants to briefly share a nonconfidential description of their asset, current partnering objective, and most important readiness or engagement need. The goal is to identify where further evaluation or collaboration may be useful.
Who Should Request an Invitation
This gathering is particularly relevant for:
Companies that own or control a preclinical or clinical biotech asset
Founders and executives preparing for U.S. investment or licensing discussions
Scientific and business-development leaders pursuing pharmaceutical partnerships
Organizations seeking to improve asset positioning, evidence preparation, legal readiness, or U.S. engagement strategy
Representatives authorized to discuss the asset and evaluate potential follow-up support
General networking, service promotion, and attendance without a specific asset or partnering objective are not the focus of this gathering.
Program
8:00–8:30 AM — Breakfast networking and participant introductions
8:30–8:40 AM — Opening remarks and purpose
8:40–9:28 AM — Four practical perspectives
9:28–9:55 AM — Participant assets, partnering needs, and potential collaboration
9:55–10:00 AM — Closing and next steps
Registration
Attendance is limited and subject to approval to maintain a relevant, candid, and productive conversation.
When requesting an invitation, please provide a concise, nonconfidential description of:
The asset or program you represent
Its development stage and therapeutic area
Your organization’s rights or relationship to the asset
The U.S. investment, licensing, or partnership objective you are pursuing
The most important question or readiness gap you hope to address
Submitting a registration request does not guarantee admission. Approved participants will receive the exact venue address before the event.
Presented by TopContenders Network
Breakfast Sponsor: THC Lawyers
Important Notice
This independent gathering is not affiliated with or endorsed by BioTechX USA or Terrapinn. Participation is for education, professional discussion, and networking only. It does not constitute investment, legal, regulatory, medical, or transaction advice; an offer or solicitation; or a commitment to invest, license, partner, provide services, or make introductions. Discussions should remain nonconfidential unless the relevant parties enter into a separate written agreement.